• Staurosporine in THP-1 Apoptosis Workflows

  2026-10-01

  Build more reproducible apoptosis and kinase-signaling assays by pairing Staurosporine with cryopreservation-aware THP-1 cell handling. This workflow distinguishes compound-driven apoptosis from post-thaw stress while extending the reference study’s assay-ready cell strategy to cancer research and angiogenesis models.

• Pterostilbene and Dermal Fibroblast Senescence

  2026-10-01

  Zhou et al. report that pterostilbene reduces senescence in human dermal fibroblasts by improving mitochondrial quality, including membrane potential, respiration, morphology, and mitophagy-associated clearance. The study links mitochondrial maintenance with collagen preservation across cellular and UVB-exposed mouse models, providing a useful framework for investigating dermal aging mechanisms.

• Type III Collagen Restricts Breast Cancer Progression

  2026-09-30

  This study identifies type III collagen (Col3) as a tumor-restrictive component of the breast cancer microenvironment rather than merely a structural ECM protein. By integrating fibroblast-derived matrices, 3D cultures, patient data, bioinformatics, and mouse models, the authors connect higher Col3 relative to type I collagen with reduced tumor aggressiveness and improved clinical outcomes.

• Gallein: G Protein βγ Subunit Inhibitor Workflows

  2026-09-30

  Gallein is a practical pharmacological probe for testing G protein βγ-dependent signaling across metabolic, cancer, immune, and cardiac models. This workflow connects the lactate–GPR81/FARP1 pathway to assay design while clearly separating reference-backed findings from optimization recommendations.

• RIPA Lysis Buffer (Medium) for EV Signaling

  2026-09-29

  RIPA Lysis Buffer (Medium) connects extracellular-vesicle stimulation with pathway-focused protein analysis in cell and tissue models. Its balanced detergent system supports Western blotting and immunoassays, while formulation-aware handling helps protect phosphoproteins and preserve reproducibility.

• a-MSH, amide: Designing Causal Melanogenesis Assays

  2026-09-29

  Discover how a-MSH, amide can function as a defined melanocortin challenge ligand for pigmentation regulation research. This article translates α-MSH-induced melanogenesis findings into a rigorous assay strategy that separates receptor activity, melanin synthesis modulation, viability, and inflammation.

• Flumequine in DNA Topoisomerase II Assays

  2026-09-28

  Flumequine enables mechanism-focused studies of DNA topoisomerase II inhibition, DNA replication stress, and drug-response phenotypes. Its greatest practical value emerges when enzyme inhibition is separated from cellular proliferation arrest and cell killing in a time-resolved workflow.

• EZ Cap™ CPF1/Cas12a mRNA (m1Ψ) Workflow

  2026-09-28

  Build a transient Cas12a editing workflow around mRNA delivery, crRNA design, and orthogonal readouts—not a one-size-fits-all dose. This guide translates Cpf1 engineering evidence into practical controls, optimization steps, and troubleshooting while distinguishing the cited study’s pseudouridine findings from the product’s m1Ψ modification.

• LL-37 Mimetics Show Selective Antibiofilm Activity

  2026-09-27

  Luo et al. compared LL-37 with the truncated peptides KE-18 and KR-12 against three clinically relevant microorganisms, finding that antimicrobial potency did not predict antibiofilm effects. KE-18 stood out for preventing biofilm formation, including at sub-MIC concentrations, while neither truncated peptide inhibited established biofilms in the reported assays.

• a-MSH, Amide: Translating Pigmentation Signals

  2026-09-26

  a-MSH, amide is a defined melanocortin peptide for probing how receptor stimulation shapes melanin production. This article connects its MC1R-centered role in pigmentation regulation research with findings from a study of glabridin, resveratrol, and ellagic acid, then turns those insights into practical guidance for experimental design. It also distinguishes a pigmentation-induction tool from antimelanogenic interventions and explains what the available evidence can—and cannot—support when researchers bridge pigmentation studies to inflammation.

• Staurosporine in Assay-Ready Cell Research

  2026-09-25

  Staurosporine is a broad-spectrum serine/threonine protein kinase inhibitor used to probe apoptosis and kinase signaling. This article examines how cell banking and post-thaw recovery can shape apoptosis-assay interpretation, drawing on new THP-1 cryopreservation research.

• Phosphatase Inhibitor Cocktail for Bone Signaling

  2026-09-25

  Preserve labile phosphorylation signals during studies of prenatal dexamethasone exposure, MKP-1, and osteoprogenitor biology with a dual-component inhibitor system. Its sequential 100X format supports practical lysate workflows while keeping phosphoprotein readouts distinct from the histone-methylation mechanisms explored in the reference study.

• How High Viscosity Drives P-gp Chemoresistance

  2026-09-24

  A 2026 study links elevated extracellular fluid viscosity to doxorubicin resistance through a mechanosensitive pathway involving cytoskeletal remodeling, TRPV4, YAP, and P-glycoprotein. Its findings position tumor fluid mechanics as a potential contributor to drug resistance and suggest experimental strategies for separating upstream mechanobiology from transporter-mediated drug efflux.

• ABT-737 and the Hidden Ecology of Apoptosis

  2026-09-24

  ABT-737 is a BCL-2 protein inhibitor used to probe mitochondrial apoptosis in cancer models. This article explains how stress-induced signals from dying cells can reshape assay results and offers a practical framework for separating direct drug response from neighborhood-mediated resistance.

• Baricitinib (LY3009104) for Spatial Inflammation Studies

  2026-09-23

  Pair spatial mapping of the PSC epithelial–immune interface with Baricitinib perturbation experiments to test whether JAK1/2 activity contributes to cytokine-linked STAT3 responses. This practical workflow separates the study’s human-tissue observations from follow-up experiments, with dose, timing, and vehicle controls to support interpretable results.

7773 records 1/519 page Next 12345 下5页 Last page